Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Alabama at Birmingham
Eligible participants include all children admitted to the PICU at Children's of Alabama with a diagnosis of RSV infection and requiring positive pressure ventilation, invasive or noninvasive, including bilevel positive airway pressure (BiPAP) or high flow nasal cannula (HFNC) oxygen (ie, \>1 L/kg/min of flow, with 5 L/min flow for children weighing \<5 kg). During hospitalization, all patients will be treated according to the American Academy of Pediatrics guidelines for the management of bronchiolitis, primarily supportive care. Participants will then be randomized according to a permuted-block design to receive either placebo (saline) or AZM (Fresenius Kabi) at 10mg/kg/d (ie, standard dose) or 20mg/kg/d (ie, high dose) intravenously every 24 hours for 3 days. All biologic samples collected will be analyzed in the PI's lab at the University of Alabama at Birmingham. Drug pharmacokinetics will be performed at the Pharmaceutical Sciences Research Institute of Samford University, Birmingham, AL.
Age
0–16
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Admission to the PICU with RSV infection
Need for positive pressure ventilation (invasive and non-invasive)
Randomization and drug/placebo initiation within 48 hours of admission to Pediatric Intensive Care Unit
You may not be if
Azithromycin use within 7 days of PICU admission
Contraindication to azithromycin use including:
* Patients with electrocardiogram QT interval corrected for heart rate (Qtc) ≥ 450 ms
* Patients with significant hepatic impairment (direct bilirubin \>1.5 mg/dL)
* Known hypersensitivity to azithromycin, erythromycin, any macrolide, or ketolide drug
* Cardiac arrhythmia
History of pyloric stenosis
Immunocompromised children (any cause)
Current use of any medication known to cause QT prolongation